Generating a Long-term Immune Response to Merkel Cell Carcinoma ASPIRE Award (ASPIRE I: 2020-2021; ASPIRE II: 2022-PRESENT) Paul Nghiem, MD, PhD, University of Washington Read More
Selectively Targeting Non-Proliferating Cancer Cells ASPIRE Award (2020-2021; ASPIRE II: 2022-PRESENT) René Bernards, PhD, Netherlands Cancer Institute (Principal); Anthony Letai, MD, PhD, Dana-Farber Cancer Institute Read More
Targeting the “Undruggable” in Cancer Using Chemoproteomics-Enabled Covalent Ligand Discovery Platforms ASPIRE AWARD (ASPIRE I: 2018-2019; ASPIRE II: 2020-PRESENT) Daniel Nomura, PhD, University of California, Berkeley Read More
Targeting Chordoma Spinal Tumors Using Rational Drug Design In Partnership with Chordoma Foundation (2020-2022) David Drewry, PhD, University of North Carolina, Chapel Hill; Opher Gileadi, PhD, University of Oxford; Paul Workman, PhD, Institute for Cancer Research Read More
Using a High-Fiber Diet to Improve Melanoma Patients’ Response to Immunotherapy ASPIRE Award (2019-Present) Jennifer McQuade, MD, MS (Principal); Jennifer Wargo, MD, MMSc; and Carrie Daniel-MacDougall, PhD, MPH, The University of Texas MD Anderson Cancer Center Read More
Using an FDA-Approved, Anti-Arthritis Drug to Improve Outcomes in Pancreatic Ductal Adenocarcinoma (PDAC) ASPIRE Award (2019-2022) Cullen Taniguchi, MD, PhD (Principal); Anirban Maitra, MD; and Eugene Jon Koay, MD, The University of Texas MD Anderson Cancer Center Read More
